Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel J. O'Connell
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Beta
- 0.33
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -11.72
Financials
Revenue
$0.00-100.0%Net Income
$-25.37MEBITDA
$-24.36MFree Cash Flow
$-26.65MEPS (diluted)
$-0.35Shares Outstanding (diluted)
72.32M+152.4%Operating Expenses
$25.81MCash & Debt
$78.60MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-121.33M | $-2.00 |
| 2024 | $0.00 | $-102.33M | $-1.71 |
| 2023 | $0.00 | $-52.37M | $-1.08 |
| 2022 | $0.00 | $-42.86M | $-1.06 |
| 2021 | $0.00 | $-100.61M | $-2.63 |
| 2020 | $1.44M | $-7.33M | $-0.26 |
| 2019 | $1.70M | $-7.91M | $-0.20 |
Valuation
ABOShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150-6.25%Social Signal Score
Mentions (10)
- Newsmarketbeat.com·27d ago·Neutral
Acumen Pharmaceuticals Q3 Earnings Call Highlights Acumen Pharmaceuticals NASDAQ: ABOS said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble amyloid-beta oligomers in patients with Alzheimer's disease.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in November 2026 IND filing for the Enhanced Brain Delivery™ (EBD®) program lead clinical candidate targeted for mid-2027 Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and oper
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
…al at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key poster presentations at the upcoming 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Bos…
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
… Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026 NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conferen…
View source ↗ - Newszacks.com·62d ago·Negative
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
View source ↗ - Newsglobenewswire.com·73d ago·Neutral
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
Acumen Pharmaceuticals Q2 Earnings Call Highlights Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2026 and provided a business update.
View source ↗
Earnings
Thu, Mar 25(in 4 months)
Consensus estimate $-0.40 per share
Typical surprise +14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Oct 26$-0.35 vs $-0.39beat
- Tue, Aug 11$-0.45 vs $-0.36miss
- Tue, May 12$-0.33 vs $-0.40beat
- Thu, Mar 26$-0.41 vs $-0.50beat
- Wed, Nov 12$-0.44 vs $-0.63beat
- Tue, Aug 12$-0.68 vs $-0.54miss
Estimates and results for ABOS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ABOS officers and directors.
- Bought
- —
- Sold
- $625k
0 trades
48 trades
- Porter Derrellsold
- Porter Derrellsold
- Porter Derrellsold
- Fountain Nathan Bsold
- Meisner Derek Msold
- Meisner Derek Msold
- Meisner Derek Msold
- Meisner Derek Msold
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ABOS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
